Xiang Zhang Selected Research

Diffuse Brain Injuries (Diffuse Brain Injury)

11/2007	Posttraumatic secondary brain insults exacerbates neuronal injury by altering metabotropic glutamate receptors.
12/2006	Metabotropic glutamate receptor antagonists and agonists: potential neuroprotectors in diffuse brain injury.
6/2005	Altered expression patterns of metabotropic glutamate receptors in diffuse brain injury.
10/2003	Changes of metabotropic glutamate receptor subtype 1a in diffuse brain injury with secondary brain insults and the effects of 2-methyl-4-carboxyphenylglycine.
10/2003	[Changes and effects of group II metabotropic glutamate receptors in the cerebral cortex of rats after diffuse brain injuries coupled with hypopiesia secondary brain insults].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiang Zhang Research Topics

Disease

218	Neoplasms (Cancer) 11/2022 - 01/2002
54	Glioma (Gliomas) 01/2022 - 01/2002
46	Inflammation (Inflammations) 09/2022 - 01/2012
38	Breast Neoplasms (Breast Cancer) 11/2022 - 05/2011
35	Glioblastoma (Glioblastoma Multiforme) 03/2022 - 09/2006
33	Neoplasm Metastasis (Metastasis) 12/2021 - 01/2002
31	Carcinogenesis 11/2022 - 02/2005
27	Infections 12/2022 - 12/2004
24	Insulin Resistance 01/2022 - 01/2012
23	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 12/2011
20	Body Weight (Weight, Body) 01/2021 - 01/2012
18	Stroke (Strokes) 11/2022 - 04/2006
18	Prostatic Neoplasms (Prostate Cancer) 05/2022 - 04/2006
16	Hypoxia (Hypoxemia) 01/2022 - 07/2011
15	Wounds and Injuries (Trauma) 07/2022 - 09/2007
15	Fatty Liver 01/2022 - 01/2013
15	Non-alcoholic Fatty Liver Disease 01/2022 - 07/2012
15	Neuroinflammatory Diseases 01/2022 - 08/2014
14	Ischemic Stroke 01/2022 - 04/2006
13	Pain (Aches) 04/2022 - 06/2013
12	Lung Neoplasms (Lung Cancer) 01/2022 - 06/2008
11	Fibrosis (Cirrhosis) 09/2022 - 01/2014
11	Obesity 01/2021 - 07/2012
10	Pancreatic Neoplasms (Pancreatic Cancer) 02/2022 - 06/2014
10	Type 2 Diabetes Mellitus (MODY) 01/2020 - 07/2012
9	Carcinoma (Carcinomatosis) 05/2022 - 01/2009
9	COVID-19 02/2022 - 01/2020
9	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2016
9	Rheumatoid Arthritis 03/2020 - 12/2016
9	Weight Loss (Weight Reduction) 05/2019 - 10/2015
8	Liver Neoplasms (Liver Cancer) 06/2022 - 06/2012
8	Cognitive Dysfunction 04/2022 - 05/2015
8	Familial Exudative Vitreoretinopathies 09/2021 - 01/2019
8	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2017 - 09/2009
7	Alcoholic Fatty Liver 06/2022 - 01/2013
7	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 04/2012
7	Lymphatic Metastasis 01/2022 - 12/2008
7	Hemorrhage 03/2021 - 09/2003
7	Renal Cell Carcinoma (Grawitz Tumor) 01/2021 - 02/2016
6	Virus Diseases (Viral Diseases) 01/2022 - 01/2020
6	Retinal Detachment (Retinal Detachments) 01/2022 - 12/2008
6	Atherosclerosis 01/2022 - 09/2007
6	Osteoarthritis 01/2022 - 03/2014
6	Parathyroid Neoplasms (Parathyroid Neoplasm) 12/2021 - 01/2018
6	Uterine Cervical Neoplasms (Cancer of the Cervix) 10/2021 - 09/2009
6	Stomach Neoplasms (Stomach Cancer) 01/2021 - 12/2008
6	Astrocytoma (Pilocytic Astrocytoma) 03/2011 - 02/2008

Drug/Important Bio-Agent (IBA)

65	Proteins (Proteins, Gene)FDA Link 10/2022 - 07/2005
48	Biomarkers (Surrogate Marker)IBA 06/2022 - 03/2005
36	Pharmaceutical PreparationsIBA 07/2022 - 09/2007
30	Biological ProductsIBA 01/2022 - 09/2006
30	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 02/2010
26	Messenger RNA (mRNA)IBA 01/2022 - 06/2005
22	CytokinesIBA 03/2022 - 12/2013
17	MicroRNAs (MicroRNA)IBA 03/2022 - 03/2012
17	Retinaldehyde (Retinal)IBA 01/2022 - 09/2009
17	Long Noncoding RNAIBA 01/2022 - 01/2016
17	Small Interfering RNA (siRNA)IBA 01/2022 - 09/2006
17	LipidsIBA 08/2021 - 01/2012
15	Hormones (Hormone)IBA 11/2022 - 05/2003
15	RNA (Ribonucleic Acid)IBA 03/2022 - 02/2010
15	ResveratrolIBA 06/2021 - 04/2006
12	LipopolysaccharidesIBA 01/2022 - 05/2015
12	Therapeutic UsesIBA 01/2022 - 12/2016
12	Insulin (Novolin)FDA Link 01/2021 - 07/2012
11	CateninsIBA 01/2022 - 03/2011
10	VaccinesIBA 12/2022 - 12/2009
10	Temozolomide (Temodar)FDA LinkGeneric 03/2022 - 06/2012
10	salicylhydroxamic acid (SHAM)IBA 05/2019 - 10/2015
9	ChemokinesIBA 07/2022 - 01/2011
9	LigandsIBA 05/2022 - 08/2010
9	Interleukin-6 (Interleukin 6)IBA 02/2022 - 12/2006
9	ErbB Receptors (EGF Receptor)IBA 01/2022 - 06/2008
9	Peptides (Polypeptides)IBA 01/2021 - 06/2012
9	Transcription Factors (Transcription Factor)IBA 10/2020 - 01/2009
8	CollagenIBA 09/2022 - 08/2015
8	Estrogen ReceptorsIBA 01/2022 - 04/2006
8	CopperIBA 01/2021 - 08/2013
8	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2020 - 09/2008
8	Blood Glucose (Blood Sugar)IBA 01/2019 - 07/2012
8	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2019 - 10/2015
8	SurvivinIBA 08/2018 - 07/2005
7	AntioxidantsIBA 07/2022 - 12/2007
7	AntibodiesIBA 06/2022 - 01/2011
7	Anti-Bacterial Agents (Antibiotics)IBA 10/2018 - 04/2009
6	Bile Acids and Salts (Bile Acids)IBA 11/2022 - 10/2015
6	CholesterolIBA 01/2022 - 01/2016
6	Caspase 3 (Caspase-3)IBA 10/2021 - 02/2007
6	FructoseIBA 01/2021 - 08/2013
6	ZincIBA 01/2021 - 01/2012
6	AndrogensIBA 01/2021 - 12/2007
6	Indicators and Reagents (Reagents)IBA 11/2019 - 04/2011
5	HydrogelsIBA 07/2022 - 11/2017
5	AntigensIBA 05/2022 - 01/2017

Therapy/Procedure

114	Therapeutics 11/2022 - 01/2007
36	Drug Therapy (Chemotherapy) 03/2022 - 09/2006
17	Radiotherapy 10/2021 - 08/2007
12	Immunotherapy 06/2022 - 12/2006
7	Transplantation 11/2018 - 05/2014
6	Catheters 02/2022 - 05/2003